The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Yes, agreed.
No mention of EUA application; just more r read watch from a research company.
Unless there is a change of hands we haven’t got the team to bring this to commercialisation imo.
When was the last time our CEO communicated with us?
Let’s hope we receive positive news on the 25th.
Doc
Agreed that the article is a joke.
What is also a joke is the lack of comms from the company.
They have always been so poor at responding to emails, putting out supporting tweets, providing updates for investors, etc.
I would say an email of this nature should be sent to Brooke, but I didn’t receive a reply to my last two attempts.
Is it too much to expect a tweet about how the conference is going, anything learnt, any networking news, the mood, etc. if there’s nothing to tweet or mention from such a positive event then …?
Very amateur; unfortunately I’m stuck in this for a long time.
GLA LTHs.
This is simply to do with the timelines, again.
We are now looking at another trial which will take place and complete within the next year, hopefully.
MMS will manipulate the stock until the next batch.
Some very interesting delayed trades, of the large variety.
Anthony
To make it clear, as this has been said many times.
If the company has anything of value to the market, they have to, by law, report it immediately.
Failure to do so results in….
So, have they any news?
Maybe they are still busy at their computers half hour before the presentation?
GL
Doc
Agreed completely
I hope you’re right doc.
ATB
Doc
The point is they have revealed nothing of significance 1 working day before the Conference.
Whatever they are delivering on Monday will be known to the team, now.
I have previously said, ‘I hope I’m wrong’ but I don’t see how it can be any different?
For me, there are only disappointments to come, again.
No RNS as the Conference opens, so clearly nothing of significance has been unearthed that is market sensitive.
RM will not resign as he is paid a lot of money, same as Boris the berk.
Can LTHs suffer any more at the hands of this company?
Of course, there is Monday!
Then, just like that, two come along together.
I could comment, but I just see green.
What a moby
Or a 1 post wonder to deramp!
Why are you here, out of interest?
Axe
You must be very wealthy if you just took a ‘punt’ for £20k.
GL
If there are any true gems doc we will find out via an RNS, in good time.
That will hopefully be next week.
Manifesto
I hope you’re well.
As much as I would like an application for EUA, I don’t see it. There was much talk from RM pre-P3 readout that if data was good and Covid was still around then EUA would be applied for.
I have not seen anything from the Company since that dreadful day that suggests EUA would be made?
Pre-p3 readout there was an incredible amount of evidence on here from so many amazing posters; hence why I over indulged in this share.
I would love nothing more than impressive data to be unearthed from the DD, but until that happens I don’t see it.
RM talks of another trial. We just failed a 623 patient one on both primary and secondary endpoints, due to SOC changes.
Why will a new trial be any different in terms of results, when SOC will remain as high?
A takeover may come with new data, but that won’t recoup all my losses and Synairgen definitely do not have the scope, ability or workforce to bring this expensive drug to market imo.
We needed amazing results from the Sprinter trial , as whatever people think on here, the cost of drugs DEFINITELY matter! I know we have discussed price of ICU stays v our drug but there are much cheaper alternatives that Governments will prefer to invest in, unless the evidence is overwhelming imo.
I hope I am wrong and that something can be salvaged from the DD/Active data, wherever that is?
GLA LTHs
It’s pretty clear that they haven’t yet finished analysing the data, which is cutting it fine if that’s the case.
‘As announced on 21 February 2022, Synairgen is in the process of analysing the topline and full dataset from the SPRINTER Phase 3 study in order to better understand all of the findings. The findings of this analysis will be announced ‘without delay’ once complete in accordance with regulatory obligations and presented and/or published in a peer-review journal.’
‘The SPRINTER trial pointed to an encouraging trend in prevention of progression to severe disease and death (36% reduction in the pre-defined per protocol population), which the Company and its clinical advisors strongly believe merits further investigation in a platform trial which the Company is actively investigating.’
Hopefully, an RNS on Monday.
GLA
Thanks Titania.
More glowing evidence; does it amount to anything for us?
ATB
Manifesto
Following the disappointing failed endpoints last time, I think it’s sensible to be level headed.
I don’t see how ramping this thing up will affect anything.
The results of the DD are nearly upon us; time will tell.
As I’ve said before, I won’t be buying any more shares as I’ve invested more than enough in this company.
I sincerely hope that we recover as it means I can retire earlier than planned, but unless they uncover some gems it won’t.
I’m not sure where you get 10p and 15p from? The price is 24p and I have many of them, they are the facts for me.
GLA
Manifesto
Sorry to be a fly in the ointment but ‘pretty risk free?’
I doubt many will agree with you on that one; a very naive view.
I will never think that way again regarding shares on the AIM market.
GLA LTHs
Timster
MMs will delay trades every day to manipulate the SP.
GLA